Published in Cancer J on July 30, 2015
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med (2016) 1.47
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther (2016) 0.86
Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget (2016) 0.79
Erythropoietin increases macrophage-mediated T cell suppression. Cell Immunol (2016) 0.78
Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Plasticity of CD4+ T cell lineage differentiation. Immunity (2009) 8.08
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 7.26
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med (2014) 6.06
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med (2014) 3.86
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 3.40
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature (2014) 3.16
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol (2011) 2.89
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol (2014) 2.82
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell (2011) 2.70
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett (2008) 2.64
Inhibitory effects of B cells on antitumor immunity. Cancer Res (2006) 2.57
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 2.40
p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem (1997) 2.37
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol (2015) 2.32
Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol (2010) 2.25
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 2.25
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 2.25
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res (2013) 2.19
Tumor-associated neutrophils: friend or foe? Carcinogenesis (2012) 2.15
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature (2015) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res (2009) 2.00
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (2014) 2.00
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med (1999) 1.82
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature (2014) 1.79
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.73
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res (1983) 1.66
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat (2010) 1.64
Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer (2005) 1.63
Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol (2011) 1.58
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology (2013) 1.57
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res (2013) 1.57
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol (2013) 1.55
Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer (2011) 1.55
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54
Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer (2013) 1.54
Forty-year journey of angiogenesis translational research. Sci Transl Med (2011) 1.51
Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci (2013) 1.50
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell (2014) 1.43
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature (2015) 1.42
High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer (2008) 1.41
Dendritic cells in the cancer microenvironment. J Cancer (2012) 1.40
IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ (2010) 1.39
B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother (2000) 1.32
Dendritic cells and immunity against cancer. J Intern Med (2011) 1.32
Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol (2007) 1.30
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res (2009) 1.24
Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res (2011) 1.22
Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene (2011) 1.18
How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev (2011) 1.15
Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood (2000) 1.14
The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets (2010) 1.10
Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Hum Pathol (1996) 1.06
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med (2005) 4.31
Cancer: an inflammatory link. Nature (2004) 3.88
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85
Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol (2009) 2.84
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res (2005) 1.84
alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol (2006) 1.81
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med (2006) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol (2003) 1.63
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
MMP9 potentiates pulmonary metastasis formation. Cancer Cell (2002) 1.57
Inflammation, proteases and cancer. Eur J Cancer (2006) 1.52
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech (2010) 1.35
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Soluble mediators of inflammation during tumor development. Adv Cancer Res (2005) 1.24
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Superoxide dismutase protects against apoptosis and alveolar enlargement induced by ceramide. Am J Physiol Lung Cell Mol Physiol (2008) 1.17
A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. J Am Chem Soc (2006) 1.09
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol (2013) 1.07
Early neoplastic progression is complement independent. Neoplasia (2005) 1.07
Inflaming gastrointestinal oncogenic programming. Cancer Cell (2008) 1.07
Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer (2011) 1.04
TIMP-1 alters susceptibility to carcinogenesis. Cancer Res (2004) 1.01
Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 0.99
Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc (2006) 0.99
Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation (2002) 0.97
RECKing MMP function: implications for cancer development. Trends Cell Biol (2002) 0.96
Delineating protease functions during cancer development. Methods Mol Biol (2009) 0.93
Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res (2007) 0.91
IKKalpha at the crossroads of inflammation and metastasis. Cell (2007) 0.89
Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem (2007) 0.89
Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. Cancer Res (2007) 0.89
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res (2010) 0.89
Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol Endocrinol (2011) 0.88
MR imaging of tumor-associated macrophages. Oncoimmunology (2012) 0.88
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev (2013) 0.87
Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem (2008) 0.86
Ceramide causes pulmonary cell apoptosis and emphysema: a role for sphingolipid homeostasis in the maintenance of alveolar cells. Proc Am Thorac Soc (2006) 0.86
Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog (2011) 0.86
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. Curr Protoc Cytom (2005) 0.83
HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription. Mol Endocrinol (2011) 0.83
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. Int J Cancer (2010) 0.83
The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer. Am J Pathol (2012) 0.82
Optical imaging of the peri-tumoral inflammatory response in breast cancer. J Transl Med (2009) 0.81
Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev (2008) 0.81
Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. J Mammary Gland Biol Neoplasia (2014) 0.79
Histamine restricts cancer: nothing to sneeze at. Nat Med (2011) 0.78
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther (2006) 0.76
AACR Cancer Progress Report 2016. Clin Cancer Res (2016) 0.75
Poker face no more: cancer recurrence reveals its hand. Nat Med (2013) 0.75
Some DCs are "B"etter. Immunity (2013) 0.75
Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. US Oncol (2009) 0.75
Multiplexed immunohistochemistry image analysis using sparse coding. Conf Proc IEEE Eng Med Biol Soc (2017) 0.75